Skip to main content
SpringerLink
Log in

Anti-angiogenesis Therapy and Strategies for Integrating It with Adjuvant Therapy

  • Conference paper
Adjuvant Therapy of Primary Breast Cancer VI

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 152))

Abstract

The growth of tumors above about 1 mm in diameter requires angiogenesis, the development of a new blood supply, from pre-existing vasculature (Folkman 1990). This applies to both the primary and secondary lesions. Angiogenesis is also essential for systemic metastasis, and it has recently been shown that it is essential for local invasion (Skobe et al. 1997). Normal vasculature is quiescent and each endothelial cell divides only once in 10 years, apart from the endometrial and ovarian angiogenesis during the menstrual cycle and during wound healing. In human tumors the number of dividing endothelial cells may be 50 times greater than in normal tissue. These vessels are leaky, have upregulated vascular growth factor receptors and cell adhesion molecules and are in a procoagulant state. Thus they provide a new therapeutic target with many factors differently expressed between tumor and normal endothelium. This review describes some of the angiogenic pathways and discusses how emerging anti-angiogenic drugs can be integrated into adjuvant trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM (1995) Synergistic effect of vascular endothelial growth-factor and basic fibroblast growth-factor on angiogenesis in vivo. Circulation 92:365–371

    CAS  Google Scholar 

  • Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407

    Article  PubMed  CAS  Google Scholar 

  • Brooks PC (1996) Cell-adhesion molecules in angiogenesis. Cancer Metastasis Rev 15:187–194

    Article  PubMed  CAS  Google Scholar 

  • Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha-v-beta-3 blocks in human breast-cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822

    Article  PubMed  CAS  Google Scholar 

  • Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition — a review of antitumor activity. Ann Oncol 6:967–974

    PubMed  CAS  Google Scholar 

  • Bunn HF, Poyton RO (1996) Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76:839–885

    PubMed  CAS  Google Scholar 

  • Cao YH, Chen A, An SSA, Ji RWD, Davidson D, Cao YM, Llinas M (1997) Kringle-5 of plasminogen is a novel inhibitor of endothelial-cell growth. J Biol Chem 272:22924–22928

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet P, MacKman N, Moons L, Luther T, Gressens P, Vanvlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, Collen D (1996) Role of tissue factor in embryonic blood-vessel development. Nature 383:73–75

    Article  PubMed  CAS  Google Scholar 

  • Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L (1994) The fibronectin isoform containing the ed-b oncofetal domain — a marker of angiogenesis. Int J Cancer 59:612–618

    Article  PubMed  CAS  Google Scholar 

  • Chan HY, Harris AL (1996) Gene therapy targeting to tumor endothelium. In: Sobol RE, Scanlon KJ (eds) The internet book of gene therapy — cancer therapeutics. Appleton and Lange, Stamford, pp 211–227

    Google Scholar 

  • Claffey KP, Robinson GS (1996) Regulation of vegf/vpf expression in tumor-cells — consequences for tumor-growth and metastasis. Cancer Metastasis Rev 15:165–176

    Article  PubMed  CAS  Google Scholar 

  • Clapp C, Delaescalera GM (1997) Prolactins — novel regulators of angiogenesis. News Physiol Sci 12:231–237

    CAS  Google Scholar 

  • Czubayko F, Liaudetcoopman EDE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A (1997) A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3:1137–1140

    Article  PubMed  CAS  Google Scholar 

  • Dach GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KMS, Stratford IJ, Harris AL (1997) Targeting gene expression to hypoxic tumor cells. Nat Med 3:515–520

    Article  Google Scholar 

  • Damert A, Ikeda E, Risau W (1997) Activator-protein-1 binding potentiates the hypoxia-in-ducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-en-dothelial growth-factor expression in c 6 glioma-cells. Biochem J 327:419–423

    PubMed  CAS  Google Scholar 

  • Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, Depooter C, Martin M, Vanoosterom AT (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth-factor and vascular endothelial growth-factor in sera of cancer patients. Br J Cancer 76:238–243

    Article  PubMed  CAS  Google Scholar 

  • Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL (1997) Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in-situ of the breast. J Pathol 182:414–420

    Article  PubMed  CAS  Google Scholar 

  • Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6

    Article  PubMed  CAS  Google Scholar 

  • Fox SB, Harris AL (1997) Markers of tumor angiogenesis — clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs 15:15–28

    Article  PubMed  CAS  Google Scholar 

  • Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 177:275–283

    Article  PubMed  CAS  Google Scholar 

  • Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL (1997 a) Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8:271–275

    Article  PubMed  CAS  Google Scholar 

  • Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL (1997b) Association of tumor angiognesis with bone-marrow micrometastases in breast-cancer patients. J Natl Cancer Inst 89:1044–1049

    Article  PubMed  CAS  Google Scholar 

  • Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of 2 angiogenic pathways by distinct alpha(v) integrins. Science 270:1500–1502

    Article  PubMed  CAS  Google Scholar 

  • Gasparini G, Harris AL (1997) p53 and angiogenesis in neoplasia. In: Klijn JGM (ed) Prognostic and predictive value of p53. Elsevier, Rotterdam, pp 115–130

    Google Scholar 

  • Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88–91

    Article  PubMed  CAS  Google Scholar 

  • Griffiths L, Dachs G, Bicknell R, Harris AL, Stratford IJ (1997) The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymi-dine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57:570–572

    PubMed  CAS  Google Scholar 

  • Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364

    Article  PubMed  CAS  Google Scholar 

  • Hildenbrand R, Dilger I, Horlin A, Stutte HJ (1995) Urokinase plasminogen-activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol Res Pract 191:403–409

    Article  PubMed  CAS  Google Scholar 

  • Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases — balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153

    Article  PubMed  CAS  Google Scholar 

  • Horak ER, Leek R, Klenk N (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer. Lancet 340:1120–1124

    Article  PubMed  CAS  Google Scholar 

  • Huang XM, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547–550

    Article  PubMed  CAS  Google Scholar 

  • Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von-Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595–10599

    Article  PubMed  CAS  Google Scholar 

  • Jagger RT, Chan HY, Harris AL (1997) Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promotors following retroviral delivery. Hum Gen Ther 8:2239–2247

    Article  Google Scholar 

  • Jain RK, Koenig GC, Dellian M, Fukumura D, Munn LL, Melder RJ (1996) Leukocyte-en-dothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev 15:195–204

    Article  PubMed  CAS  Google Scholar 

  • Kakeji Y, Teicher BA (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15:39–48

    Article  PubMed  CAS  Google Scholar 

  • Kevil CG, Debenedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS (1996) Translational regulation of vascular-permeability factor by eukaryotic initiation-factor 4 e — implications for tumor angiogenesis. Int J Cancer 65:785–790

    Article  PubMed  CAS  Google Scholar 

  • Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S (1996) Efficacy of an angiogenesis inhibitor, tnp-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77:1736–1740

    PubMed  CAS  Google Scholar 

  • Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625–4629

    PubMed  CAS  Google Scholar 

  • Lindner DJ, Borden EC (1997) Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 71:456–461

    Article  PubMed  CAS  Google Scholar 

  • Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC (1997) Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein arnt. Nature 386:403–407

    Article  PubMed  CAS  Google Scholar 

  • Mariani G, Lasku A, Balza E, Gaggero B, Motta C, Diluca L, Dorcaratto A, Viale GA, Neri D, Zardi L (1997) Tumor targeting potential of the monoclonal-antibody bc-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer 80:2378–2384

    Article  PubMed  CAS  Google Scholar 

  • Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ, Winstanley J (1997 a) Examining the technique of angiogenesis assessment in invasive brreast cancer. Br J Cancer 76:1046–1054

    Article  PubMed  CAS  Google Scholar 

  • Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J (1997b) Is a histological section representative of whole tumor vascularity in breast cancer? Br J Cancer 76:40–43

    Article  PubMed  CAS  Google Scholar 

  • Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ (1997) Hypoxia-inducible factor-I modulates gene expression in solid tumor and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104–8109

    Article  PubMed  CAS  Google Scholar 

  • Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth-factor expression. Cancer Res 56:3436–3440

    PubMed  CAS  Google Scholar 

  • McCulloch P, Choy A, Martin L (1995) Association between tumor angiogenesis and tumorcell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334–1335

    Article  PubMed  CAS  Google Scholar 

  • Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM (1996) Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56:1615–1620

    PubMed  CAS  Google Scholar 

  • Min HY, Doyle LV, Vitt CR, Zandonella CL, Strattonthomas JR, Shuman MA, Rosenberg S (1996) Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56:2428–2433

    PubMed  CAS  Google Scholar 

  • Moghaddam A, Zhang H-T, Fan T-PD, Hu D-E, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:998–1002

    Article  PubMed  CAS  Google Scholar 

  • Montrucchio G, Lupia E, Demartino A, Battaglia E, Arese M, Tizzani A, Bussolino F, Camussi G (1997) Nitric oxide mediates angiogenesis induced in vivo by platelet-activating-factor and tumor-necrosis-factor-alpha. Am J Pathol 151:557–563

    PubMed  CAS  Google Scholar 

  • Nathan CA, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG, Debenedetti A (1997) Elevated expression of eif4e and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 15:1087–1094

    Article  PubMed  CAS  Google Scholar 

  • O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao YH, Sage EH, Folkman J (1994) Angiostatin — a novel angiogenesis inhibitior that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328

    Article  PubMed  Google Scholar 

  • O’Reilly MS, Boehm T, Shing T, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285

    Article  PubMed  Google Scholar 

  • Olofsson B, Pajusola K, Kaipainen A, Voneuler G, Joukov V, Saksela O, Orpana A, Petersson RF, Alitalo K, Eriksson U (1996) Vascular endothelial growth-factor-b, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576–2581

    Article  PubMed  CAS  Google Scholar 

  • Petit AMV, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS (1997) Neutralizing antibodies against epidermal growth-factor and erbb-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo — angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523–1530

    PubMed  CAS  Google Scholar 

  • Pezzella F, Dibacco A, Andreola S, Nicholson AG, Pastorino U, Harris AL (1996) Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer 32 A:2494–2500

    Article  Google Scholar 

  • Pluda JM (1997) Tumor-associated angiogenesis — mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24:203–218

    PubMed  CAS  Google Scholar 

  • Rak J, Kerbel RS (1996) Treating cancer by inhibiting angiogenesis — new hopes and potential pitfalls. Cancer Metastasis Rev 15:231–236

    Article  PubMed  CAS  Google Scholar 

  • Relf M, Lejeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial-cell growth-factor, acidic and basic fibroblast growth-factor, tumor-growth factor-beta-1, platelet derived endothelial-cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963–969

    PubMed  CAS  Google Scholar 

  • Saleh M, Vasilopoulos K, Stylli SS, Kaye AH, Wilks AF (1996) The expression of antisense vascular endothelial growth-factor (vegf) sequences inhibits intracranial c6 glioma growth in vivo by suppressing tumor angiogenesis. J Clin Neurosci 3:366–372

    Article  PubMed  CAS  Google Scholar 

  • Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3:1222–1227

    Article  PubMed  CAS  Google Scholar 

  • Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK (1996) Flk-1 as a target for tumor-growth inhibition. Cancer Res 56:3540–3545

    PubMed  CAS  Google Scholar 

  • Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, Giavazzi R (1997) The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 8:471–479

    PubMed  CAS  Google Scholar 

  • Teicher BA (1995) Angiogenesis and cancer metastases — therapeutic approaches. Crit Rev Oncol Hematol 20:9–39

    Article  PubMed  CAS  Google Scholar 

  • Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T (1996) Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77:1101–1106

    Article  PubMed  CAS  Google Scholar 

  • Vermeiden PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Qunatification of angiogenesis in solid human tumors — an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484

    Google Scholar 

  • Waltenberger J, Mayr U, Frank H, Hombach V (1996) Suramin is a potent inhibitor of vascular endothelial growth-factor — a contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 28:1523–1529

    Article  PubMed  CAS  Google Scholar 

  • Wamil BD, Thurman GB, Sundell HW, Devore RF, Wakefield G, Johnson DH, Wang YF, Helleqvist CG (1997) Soluble e-selection in cancer patients as a marker of the therapeutic efficacy of cm 101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol 123:173–179

    Article  PubMed  CAS  Google Scholar 

  • Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis. A new significant and independent prognostic indictor in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887

    Article  PubMed  CAS  Google Scholar 

  • Wenger RH, Gassmann M (1997) Oxygen(es) and the hypoxia-inducible factor-i. Biol Chem 378:609–616

    PubMed  CAS  Google Scholar 

  • White FC, Carroll SM, Kamps MP (1995) Vegf messenger-RNA is reversibly stabilized by hypoxia and persistently stabilized in vegf-overexpressing human tumor-cell lines. Growth Factors 12:289–301

    Article  PubMed  CAS  Google Scholar 

  • Wilson WR, Pruijn FB (1995) Hypoxia-activated prodrugs as antitumor agents — strategies for maximizing tumor-cell killing. Clin Exp Pharmacol Physiol 22:881–885

    Article  PubMed  CAS  Google Scholar 

  • Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG (1997) Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81:567–574

    PubMed  CAS  Google Scholar 

  • Yue TL, Wang XK, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ (1997) 2-methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis — possible role for stress-activated protein-kinase signaling pathway and fas expression. Mol Pharmacol 51:951–962

    PubMed  CAS  Google Scholar 

  • Zabel DD, Feng JJ, Scheuenstuhl H, Hunt TK, Hussain MZ (1996) Lactate stimulation of macrophage-derived angiogenic acitivity is associated with inhibition of poly(adp-ribose) synthesis. Lab Invest 74:644–649

    PubMed  CAS  Google Scholar 

  • Zhang H-T, Craft P, Scott PAE, Ziche M, Weich HA, Harris AL, Bicknell R (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87:213–219

    Article  PubMed  CAS  Google Scholar 

  • Zhang N, Zhong R, Wang ZY, Deuel TF (1997) Human breast-cancer growth inhibited in vivo by a dominant-negative pleiotrophin mutant. J Biol Chem 272:16733–16736

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ICRF Molecular Oncology Laboratory, John Radcliffe Hospital, Oxford, 0X3 9DS, UK

    A. L. Harris

Authors
  1. A. L. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Tumordiagnostik und Prävention, Rorschacherstrasse 150, CH-9006, St. Gallen, Switzerland

    Hans-Jörg Senn

  2. Dana Farber Cancer Institute Biostatistics, 44 Binney Street, Boston, 02115, USA

    Richard D. Gelber Ph.D

  3. Ospedale Civico, CH-6900, Lugano, Switzerland

    Aron Goldhirsch

  4. Klinik C für Innere Medizin Abteilung für Onkologie und Hämatologie, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland

    Beat Thürlimann

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Harris, A.L. (1998). Anti-angiogenesis Therapy and Strategies for Integrating It with Adjuvant Therapy. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45769-2_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45771-5

  • Online ISBN: 978-3-642-45769-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation